127 related articles for article (PubMed ID: 1544593)
1. CA125 in peritoneal fluid of ovarian cancer patients.
Vergote IB; Onsrud M; Børmer OP; Sert BM; Moen M
Gynecol Oncol; 1992 Feb; 44(2):161-5. PubMed ID: 1544593
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
4. Are CASA and CA125 concentrations in peripheral blood sourced from peritoneal fluid in women with pelvic masses?
Ward BG; McGuckin MA
Cancer; 1994 Mar; 73(6):1699-703. PubMed ID: 8156497
[TBL] [Abstract][Full Text] [Related]
5. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
Hunter VJ; Weinberg JB; Haney AF; Soper JT; Lavin P; Metsch L; Knapp RC; Bast RC
Gynecol Oncol; 1990 Feb; 36(2):161-5. PubMed ID: 2404835
[TBL] [Abstract][Full Text] [Related]
6. [Fundamental and clinical study on source of CA 125 antigen in cul-de-sac fluid and translation into systemic circulation].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):390-6. PubMed ID: 2746065
[TBL] [Abstract][Full Text] [Related]
7. CA 125 in peritoneal washings and fluid: correlation with plasma CA 125 and peritoneal cytology.
Schwartz PE; Chambers SK; Chambers JT; Tilton K; Foemmel R
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):339-42. PubMed ID: 2915859
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
9. [Study of the mechanism of tumor marker CA125 in serum].
Kiyozuka Y; Noda T; Adachi S; Adachi S; Akada S; Ichijo M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1951-8. PubMed ID: 2592818
[TBL] [Abstract][Full Text] [Related]
10. [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
Ma YX; Ye F; Chen HZ; Lü WG; Xie X
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):734-9. PubMed ID: 17565840
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
Uehara T; Yoshida H; Fukuhara M; Yoshida M; Motoi N; Sugawara S; Sone M; Arai Y; Tamura K; Uno M; Ishikawa M; Kato T
Gynecol Oncol; 2020 May; 157(2):398-404. PubMed ID: 32063274
[TBL] [Abstract][Full Text] [Related]
13. Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.
Maughan TS; Fish RG; Shelley M; Jasani B; Williams GT; Adams M
Gynecol Oncol; 1988 Jul; 30(3):342-6. PubMed ID: 2839394
[TBL] [Abstract][Full Text] [Related]
14. CA 125 in peritoneal fluid: reliable values at high dilutions.
Barbati A; Anceschi MM; Di Renzo GC; Cosmi EV
Obstet Gynecol; 1992 Jun; 79(6):1011-5. PubMed ID: 1579297
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
17. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Mariani G; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(3):243-6. PubMed ID: 2778499
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of factors influencing prognosis in patients with advanced ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):564-70. PubMed ID: 2754287
[TBL] [Abstract][Full Text] [Related]
19. Ciliated ovarian adenocarcinoma cells in ascitic fluid cytology: report of a case with immunocytochemical features.
Kobayashi TK; Teraoka S; Tsujioka T; Yoshida Y
Diagn Cytopathol; 1988; 4(3):234-8. PubMed ID: 2474417
[TBL] [Abstract][Full Text] [Related]
20. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
